Adaptive Biotechnologies Corp’s recent filing unveils that its CEO and Chairman ROBINS CHAD M unloaded Company’s shares for reported $0.17 million on Mar 05 ’24. In the deal valued at $3.43 per share,48,673 shares were sold. As a result of this transaction, ROBINS CHAD M now holds 2,576,701 shares worth roughly $7.29 million.
Then, RUBINSTEIN JULIE sold 39,070 shares, generating $135,764 in total proceeds. Upon selling the shares at $3.47, the President now owns 472,754 shares.
Before that, BENZENO SHARON sold 29,390 shares. Adaptive Biotechnologies Corp shares valued at $100,994 were divested by the Chief Commercial Ofc Imm Med at a price of $3.44 per share. As a result of the transaction, BENZENO SHARON now holds 327,415 shares, worth roughly $0.93 million.
A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in early January with a ‘”a Sector outperform”‘ rating. Piper Sandler also remained covering ADPT and has increased its forecast on December 21, 2022 with a “an Overweight” recommendation from previously “Neutral” rating. Credit Suisse started covering the stock on August 25, 2022. It rated ADPT as “an Underperform”.
Price Performance Review of ADPT
On Monday, Adaptive Biotechnologies Corp [NASDAQ:ADPT] saw its stock jump 9.69% to $2.83. Over the last five days, the stock has lost -9.00%. Adaptive Biotechnologies Corp shares have fallen nearly -42.24% since the year began. Nevertheless, the stocks have fallen -66.43% over the past one year. While a 52-week high of $9.08 was reached on 01/02/24, a 52-week low of $2.56 was recorded on 04/05/24. SMA at 50 days reached $3.56, while 200 days put it at $5.03. A total of 1.49 million shares were traded, compared to the trading of 4.23 million shares in the previous session.
Levels Of Support And Resistance For ADPT Stock
The 24-hour chart illustrates a support level at 2.67, which if violated will result in even more drops to 2.52. On the upside, there is a resistance level at 2.91. A further resistance level may holdings at 3.00. The Relative Strength Index (RSI) on the 14-day chart is 39.42, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.30, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 71.88%. Stochastics %K at 12.78% indicates the stock is a buying.
How much short interest is there in Adaptive Biotechnologies Corp?
A steep rise in short interest was recorded in Adaptive Biotechnologies Corp stocks on Mar 15, 2024, dropping by -0.73 million shares to a total of 8.46 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 9.19 million shares. There was a decline of -8.63%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 7.48% of the overall stock float, the days-to-cover ratio (short ratio) fell to 5.17.
The most recent change occurred on June 03, 2022 when Piper Sandler began covering the stock and recommended ‘”a Neutral”‘ rating along with a $7.50 price target.
